In vitro susceptibility of field isolates of Leishmania donovani to miltefosine and amphotericin B: Correlation with sodium antimony gluconate susceptibility and implications for treatment in areas of endemicity

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 2, 2009, Pages 835-838

  Kumar, Dhiraj ^a   Kulshrestha, Arpita ^a   Singh, Ruchi ^a,b   Salotra, Poonam ^a  

^a SAFDARJUNG HOSPITAL   (India)

^b NATIONAL INSTITUTE OF MALARIA RESEARCH   (India)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIMONY GLUCONATE; MESSENGER RNA; MILTEFOSINE;

ADOLESCENT; ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS RESISTANCE; ENDEMIC DISEASE; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION; HUMAN; LEISHMANIA DONOVANI; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; TREATMENT RESPONSE; VISCERAL LEISHMANIASIS;

AMPHOTERICIN B; ANIMALS; ANTIMONY SODIUM GLUCONATE; ANTIPROTOZOAL AGENTS; DNA PRIMERS; DRUG RESISTANCE; HUMANS; INDIA; LEISHMANIA DONOVANI; LEISHMANIASIS, VISCERAL; PHOSPHORYLCHOLINE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 59749105928     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01233-08     Document Type: Article

References (23)

1. Beach, D. H., L. J. Goad, and G. G. Holz, Jr. 1988. Effects of antimycotic azoles on growth and sterol biosynthesis of Leishmania promastigotes. Mol. Biochem. Parasitol. 31:149-162.
2. Beach, D. H., G. G. Holz, Jr., and G. E. Anekwe. 1979. Lipids of Leishmania promastigotes. J. Parasitol. 65:201-216.
3. Croft, S. L., S. Sundar, and A. H. Fairlamb. 2006. Drug resistance in leishmaniasis. Clin. Microbiol. Rev. 19:111-126.
4. Dube, A., N. Singh, S. Sundar, and N. Singh. 2005. Refractoriness to the treatment of sodium stibogluconate in Indian kala-azar field isolates persist in in vitro and in vivo experimental models. Parasitol. Res. 96:216-223.
5. Goad, L. J., G. G. Holz, Jr., and D. H. Beach. 1984. Sterols of Leishmania species. Implications for biosynthesis. Mol. Biochem. Parasitol. 10:161-170.
6. Kothari, H., P. Kumar, S. Sundar, and N. Singh. 2007. Possibility of membrane modification as a mechanism of antimony resistance in Leishmania donovani. Parasitol. Int. 56:77-80.
7. Lee, N., S. Bertholet, A. Debrabant, J. Muller, R. Duncan, and H. L. Nakhasi. 2002. Programmed cell death in the unicellular protozoan parasite Leishmania. Cell Death Differ. 9:53-64.
8. Lira, R., S. Sundar, A. Makharia, R. Kenney, A. Gam, E. Saraiva, and D. Sacks. 1999. Evidence that the high incidence of treatment failures in Indian kala-azar is due to the emergence of antimony-resistant strains of Leishmania donovani. J. Infect. Dis. 180:564-567.
9. Mueller, M., K. Ritmeijer, M. Balasegaram, Y. Koummuki, M. R. Santana, and R. Davidson. 2007. Unresponsiveness to AmBisome in some Sudanese patients with kala-azar. Trans. R. Soc. Trop. Med. Hyg. 101:19-24.
10. Pérez-Victoria, F. J., F. Gamarro, M. Ouellette, and S. Castanys. 2003. Functional cloning of the miltefosine transporter. A novel P-type phospholipid translocase from Leishmania involved in drug resistance. J. Biol. Chem. 278:49965-49971.
11. Pérez-Victoria, F. J., M. P. Sanchez-Canete, S. Castanys, and F. Gamarro. 2006. Phospholipid translocation and miltefosine potency require both L. donovani miltefosine transporter and the new protein LdRos3 in Leishmania parasites. J. Biol. Chem. 281:23766-23775.
12. Pérez-Victoria, F. J., M. P. Sanchez-Canete, K. Seifert, S. L. Croft, S. Sundar, S. Castanys, and F. Gamarro. 2006. Mechanisms of experimental resistance of Leishmania to miltefosine: implications for clinical use. Drug Resist. Updat. 9:26-39.
13. Rakotomanga, M., P. M. Loiseau, and M. Saint-Pierre-Chazalet. 2004. Hexadecylphosphocholine interaction with lipid monolayers. Biochim. Biophys. Acta 1661:212-218.
14. Sereno, D., P. Holzmuller, I. Mangot, G. Cuny, A. Ouaissi, and J. L. Lemesre. 2001. Antimonial-mediated DNA fragmentation in Leishmania infantum amastigotes. Antimicrob. Agents Chemother. 45:2064-2069.
15. Singh, R., D. Kumar, V. Ramesh, N. S. Negi, S. Singh, and P. Salotra. 2006. Visceral leishmaniasis, or kala azar (KA): high incidence of refractoriness to antimony is contributed by anthroponotic transmission via post-KA dermal leishmaniasis. J. Infect. Dis. 194:302-306.
16. Sundar, S. 2001. Drug resistance in Indian visceral leishmaniasis. Trop. Med. Int. Health 6:849-854.
17. Sundar, S. 2001. Treatment of visceral leishmaniasis. Med. Microbiol. Immunol. 190:89-92.
18. Sundar, S., and H. W. Murray. 2005. Availability of miltefosine for the treatment of kala-azar in India. Bull. W.H.O. 83:394-395.
19. Sundar, S., and P. L. Olliaro. 2007. Miltefosine in the treatment of leishmaniasis: clinical evidence for informed clinical risk management. Ther. Clin. Risk Manag. 3:733-740.
20. Thakur, C. P., S. Narayan, and A. Ranjan. 2004. Epidemiological, clinical & pharmacological study of antimony-resistant visceral leishmaniasis in Bihar, India. Indian J. Med. Res. 120:166-172.
21. Vergnes, B., B. Gourbal, I. Girard, S. Sundar, J. Drummelsmith, and M. Ouellette. 2007. A proteomics screen implicates HSP83 and a small kinetoplastid calpain-related protein in drug resistance in Leishmania donovani clinical field isolates by modulating drug-induced programmed cell death. Mol. Cell. Proteomics 6:88-101.
22. Verma, N. K., and C. S. Dey. 2004. Possible mechanism of miltefosine-mediated death of Leishmania donovani. Antimicrob. Agents Chemother. 48:3010-3015.
23. Yardley, V., S. L. Croft, S. De Doncker, J. C. Dujardin, S. Koirala, S. Rijal, C. Miranda, A. Llanos-Cuentas, and F. Chappuis. 2005. The sensitivity of clinical isolates of Leishmania from Peru and Nepal to miltefosine. Am. J. Trop. Med. Hyg. 73:272-275.